Souhaitez-vous accéder aux communiqués récents ?
Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.
-
BOTHELL, Wash., June 17, 2021 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ: ATHA) (“Athira“), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore...
-
BOTHELL, Wash., June 14, 2021 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ: ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health...
-
– JMP Securities Life Sciences Conference – Raymond James Human Health Innovation Conference BOTHELL, Wash., June 09, 2021 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ: ATHA)...
-
BOTHELL, Wash., June 01, 2021 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ: ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health...
-
- Jefferies Healthcare Conference- Goldman Sachs 42nd Annual Global Healthcare Conference BOTHELL, Wash., May 26, 2021 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ: ATHA) (“Athira”), a late...
-
-Phase 2 trial initiation for Parkinson’s disease dementia program and IND submission for neuropsychiatric program planned by end of 2021- -Hosted educational webinar on targeting HGF/MET...
-
BOTHELL, Wash., April 21, 2021 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ: ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal...
-
Featuring leading neurologist Marwan Sabbagh, M.DWebinar to be held Thursday, April 15, at 1:30 p.m. PT / 4:30 p.m. ET BOTHELL, Wash., April 08, 2021 (GLOBE NEWSWIRE) -- Athira Pharma, Inc....
-
– LIFT-AD and ACT-AD studies evaluating ATH-1017, a once-daily investigational drug for the treatment of mild-to-moderate Alzheimer’s disease, actively enrolling patients – – IND submissions...
-
BOTHELL, Wash., March 24, 2021 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ: ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal...